{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:03:32Z","timestamp":1759334612003,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.arcmed.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T17:34:08Z","timestamp":1505756048000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mutation Frequency of Three Neurodegenerative Lysosomal Storage Diseases: From Screening to Treatment?"],"prefix":"10.1016","volume":"48","author":[{"given":"Ana Joana","family":"Duarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2017.04.001_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.beem.2015.01.001","article-title":"Innovative treatments for lysosomal diseases","volume":"29","author":"Cox","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1155\/2013\/451298","article-title":"Efficient IDUA Gene Mutation Detection with Combined Use of dHPLC and Dried Blood Samples","volume":"2013","author":"Ribeiro","year":"2013","journal-title":"ISRN Mol Biol"},{"key":"10.1016\/j.arcmed.2017.04.001_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2017.04.001_bib5","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3695","article-title":"Metachromatic leukodystrophy","author":"von Figura","year":"2001"},{"key":"10.1016\/j.arcmed.2017.04.001_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gene.2015.05.016","article-title":"Genotypic characterization of Brazilian patients with infantile and juvenile forms of metachromatic leukodystrophy","volume":"568","author":"Virgens","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.arcmed.2017.04.001_bib7","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3827","article-title":"The GM2 gangliosidoses","author":"Gravel","year":"2001"},{"key":"10.1016\/j.arcmed.2017.04.001_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10408360390247832","article-title":"Carrier testing for autosomal-recessive disorders","volume":"40","author":"Vallance","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.arcmed.2017.04.001_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00439-003-1072-8","article-title":"Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis","volume":"114","author":"Frisch","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1051\/medsci\/20072311997","article-title":"Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present]","volume":"23","author":"Laberge","year":"2007","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.arcmed.2017.04.001_bib11","first-page":"329","article-title":"GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene abnormalities in seven patients","volume":"46","author":"Tanaka","year":"1990","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0006-291X(88)80945-8","article-title":"GM2-gangliosidosis B1 variant: a wide geographic and ethnic distribution of the specific beta-hexosaminidase alpha chain mutation originally identified in a Puerto Rican patient","volume":"156","author":"Tanaka","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.arcmed.2017.04.001_bib13","first-page":"886","article-title":"GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene mutations in 11 patients from a defined region in Portugal","volume":"49","author":"dos Santos","year":"1991","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib14","first-page":"61","article-title":"GM2-gangliosidosis variant B1 disclosed during adolescence by an isolated multi-systemic involvement of the central and peripheral nervous systems","volume":"150","author":"Le Coz","year":"1994","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.arcmed.2017.04.001_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/08830738060210061101","article-title":"Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil","volume":"21","author":"Rozenberg","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.arcmed.2017.04.001_bib16","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.arcmed.2017.04.001_bib17","doi-asserted-by":"crossref","first-page":"E2189","DOI":"10.1002\/humu.21479","article-title":"IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel \u03b1-L-iduronidase (IDUA) alleles","volume":"32","author":"Bertola","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.arcmed.2017.04.001_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/humu.21327","article-title":"Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases","volume":"31","author":"Scott","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.arcmed.2017.04.001_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/GIM.0b013e3181edef5b","article-title":"Genetic screening in the Persian Jewish community: A pilot study","volume":"12","author":"Kaback","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.arcmed.2017.04.001_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/TACG.S49628","article-title":"Tay-Sachs disease: current perspectives from Australia","volume":"8","author":"Lew","year":"2015","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/gtmb.2010.0129","article-title":"Rapid and cost-effective method for the detection of the c.533G>A mutation in the HEXA gene","volume":"15","author":"Ribeiro","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.arcmed.2017.04.001_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-8981(02)00002-5","article-title":"Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards","volume":"318","author":"Chamoles","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.arcmed.2017.04.001_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1373\/clinchem.2004.047167","article-title":"Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns","volume":"51","author":"Wang","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.arcmed.2017.04.001_bib24","first-page":"194","article-title":"Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients","volume":"14","author":"Mayer","year":"2013","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.arcmed.2017.04.001_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/(SICI)1098-1004(1997)9:3<234::AID-HUMU4>3.0.CO;2-7","article-title":"Metachromatic leukodystrophy: identification of the first deletion in exon 1 and of nine novel point mutations in the arylsulfatase A gene","volume":"9","author":"Draghia","year":"1997","journal-title":"Hum Mutat"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2017.04.001_bib26","first-page":"663","article-title":"The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy","volume":"13","author":"Regier","year":"2016","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.arcmed.2017.04.001_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcmed.2017.04.001_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000439339","article-title":"Gene Therapy for Rare Central Nervous System Diseases Comes to Age","volume":"30","author":"Aubourg","year":"2016","journal-title":"Endocr Dev"},{"key":"10.1016\/j.arcmed.2017.04.001_bib29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/mt.2015.106","article-title":"Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy","volume":"23","author":"Doerr","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.arcmed.2017.04.001_bib30","doi-asserted-by":"crossref","first-page":"e20218","DOI":"10.1371\/journal.pone.0020218","article-title":"Population carrier rates of pathogenic ARSA gene mutations: is metachromatic leukodystrophy underdiagnosed?","volume":"6","author":"\u0141ugowska","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2017.04.001_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ymgme.2005.07.010","article-title":"Mutations c.459+1G>A and p.P426L in the ARSA gene: prevalence in metachromatic leukodystrophy patients from European countries","volume":"86","author":"Lugowska","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10048-003-0166-8","article-title":"Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor","volume":"5","author":"Karpati","year":"2004","journal-title":"Neurogenetics"},{"key":"10.1016\/j.arcmed.2017.04.001_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic leukodystrophy: Disease spectrum and approaches for treatment","volume":"29","author":"van Rappard","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","article-title":"Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system","volume":"29","author":"Scarpa","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib35","doi-asserted-by":"crossref","first-page":"e0135873","DOI":"10.1371\/journal.pone.0135873","article-title":"Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases","volume":"10","author":"G\u00f3mez-Grau","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2017.04.001_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","article-title":"alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients","volume":"338","author":"Hein","year":"2004","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.arcmed.2017.04.001_bib37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.arcmed.2017.04.001_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2011.10.005","article-title":"The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse","volume":"105","author":"Wang","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2013.12.007","article-title":"Long-term nonsense suppression therapy moderates MPS I-H disease progression","volume":"111","author":"Gunn","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.arcmed.2017.04.001_bib40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-010-9047-0","article-title":"Therapeutic approaches for neuronopathic lysosomal storage disorders","volume":"33","author":"Schiffmann","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.arcmed.2017.04.001_bib41","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In\u00a0vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2017.04.001_bib42","first-page":"649","article-title":"Prevention is the Best Therapy: The Geneticist's Approach","volume":"13","author":"Altarescu","year":"2016","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.arcmed.2017.04.001_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing Technologies for Gene and Cell Therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol Ther"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440917301121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440917301121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:45:09Z","timestamp":1759261509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440917301121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0188440917301121"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2017.04.001","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutation Frequency of Three Neurodegenerative Lysosomal Storage Diseases: From Screening to Treatment?","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}